Rescheduling Notification of the Public Teleconference of the President's Commission on Combating Drug Addiction and the Opioid Crisis (Commission), 32587 [2017-14835]
Download as PDF
Federal Register / Vol. 82, No. 134 / Friday, July 14, 2017 / Notices
FOR FURTHER INFORMATION CONTACT:
Gerard Poliquin, Secretary of the Board,
Telephone: 703–518–6304.
Gerard Poliquin,
Secretary of the Board.
[FR Doc. 2017–14924 Filed 7–12–17; 4:15 pm]
BILLING CODE 7535–01–P
EXECUTIVE OFFICE OF THE
PRESIDENT
Office of National Drug Control Policy
Rescheduling Notification of the Public
Teleconference of the President’s
Commission on Combating Drug
Addiction and the Opioid Crisis
(Commission)
Office of National Drug Control
Policy (ONDCP).
ACTION: Notice of rescheduling of
teleconference.
AGENCY:
ONDCP is issuing this notice
to advise the public that the
Commission is rescheduling the
teleconference of the President’s
Commission on Combating Drug
Addiction and the Opioid Crisis that
was previously scheduled for Monday,
July 17th at 4 p.m. EST. The purpose of
the meeting is to review a draft interim
report that will be posted on ONDCP’s
Commission Web site listed below
before the teleconference.
DATES: The teleconference will be held
on Monday, July 31st at 4 p.m. EST.
ADDRESSES: There will be no physical
address. The public may call (800) 260–
0718 (Access Code 426289) to listen.
Please call five minutes before the start
time. If you are part of an organization,
please try to consolidate use to as few
lines as possible.
FOR FURTHER INFORMATION CONTACT:
General information concerning the
Commission and its meetings can be
found on ONDCP’s Web site at https://
www.whitehouse.gov/ondcp/presidentscommission. Any member of the public
who wants to obtain information about
the Commission or its meetings that is
not already on ONDCP’s Web site or
who wants to submit written comments
for the Commission’s consideration may
contact Michael Passante, Designated
Federal Officer (DFO) via email at
commission@ondcp.eop.gov or
telephone at (202) 395–6709. Please
note that ONDCP may post such written
comments publicly on our Web site,
including names and contact
information that are submitted.
SUPPLEMENTARY INFORMATION: The
Commission was established in
accordance with E.O. 13784 of March
mstockstill on DSK30JT082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:44 Jul 13, 2017
Jkt 241001
29, 2017, the Commission’s charter, and
the provisions of the Federal Advisory
Committee Act (FACA), as amended, 5
U.S.C. App. 2, to obtain advice and
recommendations for the President
regarding drug issues. The Executive
Order, charter, and information on the
Members of the Commission are
available on ONDCP’s Web site. The
Commission will function solely as an
advisory body and will make
recommendations regarding policies
and practices for combating drug
addiction with particular focus on the
current opioid crisis in the United
States. The Commission’s final report is
due October 1, 2017 unless there is an
extension. Per E.O. 13784, the
Commission shall:
a. Identify and describe the existing
Federal funding used to combat drug
addiction and the opioid crisis;
b. Assess the availability and
accessibility of drug addiction treatment
services and overdose reversal
throughout the country and identify
areas that are underserved;
c. Identify and report on best practices
for addiction prevention, including
healthcare provider education and
evaluation of prescription practices,
collaboration between State and Federal
officials, and the use and effectiveness
of State prescription drug monitoring
programs;
d. Review the literature evaluating the
effectiveness of educational messages
for youth and adults with respect to
prescription and illicit opioids;
e. Identify and evaluate existing
Federal programs to prevent and treat
drug addiction for their scope and
effectiveness, and make
recommendations for improving these
programs; and;
f. Make recommendations to the
President for improving the Federal
response to drug addiction and the
opioid crisis.
Dated: July 11, 2017.
Michael Passante,
Acting General Counsel, Designated Federal
Officer.
[FR Doc. 2017–14835 Filed 7–13–17; 8:45 am]
BILLING CODE 3280–F5–P
NUCLEAR REGULATORY
COMMISSION
[NRC–2017–0001]
Sunshine Act Meeting Notice
Weeks of July 17, 24, 31, August
7, 14, 21, 2017.
PLACE: Commissioners’ Conference
Room, 11555 Rockville Pike, Rockville,
Maryland.
DATE:
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
STATUS:
32587
Public and Closed.
Week of July 17, 2017
There are no meetings scheduled for
the week of July 17, 2017.
Week of July 24, 2017—Tentative
There are no meetings scheduled for
the week of July 24, 2017.
Week of July 31, 2017—Tentative
There are no meetings scheduled for
the week of July 31, 2017.
Week of August 7, 2017—Tentative
There are no meetings scheduled for
the week of August 7, 2017.
Week of August 14, 2017—Tentative
There are no meetings scheduled for
the week of August 14, 2017.
Week of August 21, 2017—Tentative
There are no meetings scheduled for
the week of August 21, 2017.
*
*
*
*
*
The schedule for Commission
meetings is subject to change on short
notice. For more information or to verify
the status of meetings, contact Denise
McGovern at 301–415–0681 or via email
at Denise.McGovern@nrc.gov.
*
*
*
*
*
The NRC Commission Meeting
Schedule can be found on the Internet
at: https://www.nrc.gov/public-involve/
public-meetings/schedule.html.
*
*
*
*
*
The NRC provides reasonable
accommodation to individuals with
disabilities where appropriate. If you
need a reasonable accommodation to
participate in these public meetings, or
need this meeting notice or the
transcript or other information from the
public meetings in another format (e.g.,
braille, large print), please notify
Kimberly Meyer, NRC Disability
Program Manager, at 301–287–0739, by
videophone at 240–428–3217, or by
email at Kimberly.Meyer-Chambers@
nrc.gov. Determinations on requests for
reasonable accommodation will be
made on a case-by-case basis.
*
*
*
*
*
Members of the public may request to
receive this information electronically.
If you would like to be added to the
distribution, please contact the Nuclear
Regulatory Commission, Office of the
Secretary, Washington, DC 20555 (301–
415–1969), or email
Brenda.Akstulewicz@nrc.gov or
Patricia.Jimenez@nrc.gov.
E:\FR\FM\14JYN1.SGM
14JYN1
Agencies
[Federal Register Volume 82, Number 134 (Friday, July 14, 2017)]
[Notices]
[Page 32587]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-14835]
=======================================================================
-----------------------------------------------------------------------
EXECUTIVE OFFICE OF THE PRESIDENT
Office of National Drug Control Policy
Rescheduling Notification of the Public Teleconference of the
President's Commission on Combating Drug Addiction and the Opioid
Crisis (Commission)
AGENCY: Office of National Drug Control Policy (ONDCP).
ACTION: Notice of rescheduling of teleconference.
-----------------------------------------------------------------------
SUMMARY: ONDCP is issuing this notice to advise the public that the
Commission is rescheduling the teleconference of the President's
Commission on Combating Drug Addiction and the Opioid Crisis that was
previously scheduled for Monday, July 17th at 4 p.m. EST. The purpose
of the meeting is to review a draft interim report that will be posted
on ONDCP's Commission Web site listed below before the teleconference.
DATES: The teleconference will be held on Monday, July 31st at 4 p.m.
EST.
ADDRESSES: There will be no physical address. The public may call (800)
260-0718 (Access Code 426289) to listen. Please call five minutes
before the start time. If you are part of an organization, please try
to consolidate use to as few lines as possible.
FOR FURTHER INFORMATION CONTACT: General information concerning the
Commission and its meetings can be found on ONDCP's Web site at https://www.whitehouse.gov/ondcp/presidents-commission. Any member of the
public who wants to obtain information about the Commission or its
meetings that is not already on ONDCP's Web site or who wants to submit
written comments for the Commission's consideration may contact Michael
Passante, Designated Federal Officer (DFO) via email at
commission@ondcp.eop.gov or telephone at (202) 395-6709. Please note
that ONDCP may post such written comments publicly on our Web site,
including names and contact information that are submitted.
SUPPLEMENTARY INFORMATION: The Commission was established in accordance
with E.O. 13784 of March 29, 2017, the Commission's charter, and the
provisions of the Federal Advisory Committee Act (FACA), as amended, 5
U.S.C. App. 2, to obtain advice and recommendations for the President
regarding drug issues. The Executive Order, charter, and information on
the Members of the Commission are available on ONDCP's Web site. The
Commission will function solely as an advisory body and will make
recommendations regarding policies and practices for combating drug
addiction with particular focus on the current opioid crisis in the
United States. The Commission's final report is due October 1, 2017
unless there is an extension. Per E.O. 13784, the Commission shall:
a. Identify and describe the existing Federal funding used to
combat drug addiction and the opioid crisis;
b. Assess the availability and accessibility of drug addiction
treatment services and overdose reversal throughout the country and
identify areas that are underserved;
c. Identify and report on best practices for addiction prevention,
including healthcare provider education and evaluation of prescription
practices, collaboration between State and Federal officials, and the
use and effectiveness of State prescription drug monitoring programs;
d. Review the literature evaluating the effectiveness of
educational messages for youth and adults with respect to prescription
and illicit opioids;
e. Identify and evaluate existing Federal programs to prevent and
treat drug addiction for their scope and effectiveness, and make
recommendations for improving these programs; and;
f. Make recommendations to the President for improving the Federal
response to drug addiction and the opioid crisis.
Dated: July 11, 2017.
Michael Passante,
Acting General Counsel, Designated Federal Officer.
[FR Doc. 2017-14835 Filed 7-13-17; 8:45 am]
BILLING CODE 3280-F5-P